COVID Risk | Literature database and meta-analysis page 12

Last update : 2021-08-05 08:37:15 (GMT+2) | 276 factors investigated | 1766 estimates included | 219 articles processed | QC progress: 50%

Receive updates on COVID-19 risk factors

Associated factors

Risk category:

Risk name:

Outcomes

Outcome description:

Filters

Adjusted analysis:

Author:

Reset
Run a meta-analysis by selecting an Outcome & a Risk category or a Risk name & a Risk category, and click on the Submit button.

Green: significant protective factor
Red: significant risk factor
^§ adjusted estimate (see article details)
^† estimated using data reported in the article

Outcome	Risk category	Risk [exposed vs. unexposed]	Risk estimate (95% CI)	Author [URL]	View	QC
COVID-19 (severe/fatal)	Patient characteristics	BMI for Men [Obesity (>=28 kg/m2) vs. Normal (18.5–23.9 kg/m2)]	Odds ratio: 5.660 (1.800-17.750) ^§	Cai
COVID-19 (severe/fatal)	Patient characteristics	BMI for Men [Overweight (24–27.9 kg/m2) vs. Normal (18.5–23.9 kg/m2)]	Odds ratio: 1.980 (0.780-5.000) ^§	Cai
COVID-19 (severe/fatal)	Patient characteristics	BMI [Obesity (>=28 kg/m2) vs. Normal (18.5–23.9 kg/m2)]	Odds ratio: 3.400 (1.400-8.260) ^§	Cai
COVID-19 (severe/fatal)	Patient characteristics	BMI [Overweight (24–27.9 kg/m2) vs. Normal (18.5–23.9 kg/m2)]	Odds ratio: 1.840 (0.990-3.430) ^§	Cai
COVID-19 (clinical improvement)	Laboratory Findings	Lymphocyte count [Abnormal vs. Normal]	Odds ratio: 3.397 (1.195-9.565) ^§	Hou
COVID-19 (clinical improvement)	Laboratory Findings	CRP [Abnormal vs. Normal]	Odds ratio: 0.093 (0.025-0.341) ^§	Hou
COVID-19 (clinical improvement)	Patient characteristics	Age [>=60 years vs. <60 years]	Odds ratio: 0.104 (0.024-0.449) ^§	Hou
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with remdesivir vs. Placebo]	Hazard ratio: 0.700 (0.470-1.040) ^§	Beigel
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.010 (1.009-1.011) ^§	Mehra
COVID-19 (death)	Patient characteristics	BMI [1 unit increase vs. Not applicable]	Hazard ratio: 1.063 (1.060-1.067) ^§	Mehra
COVID-19 (death)	Patient characteristics	Gender [Female vs. Male]	Hazard ratio: 0.825 (0.793-0.858) ^§	Mehra
COVID-19 (death)	Patient characteristics	Ethnicity [Black vs. White]	Hazard ratio: 1.344 (1.276-1.415) ^§	Mehra
COVID-19 (death)	Patient characteristics	Ethnicity [Hispanic vs. White]	Hazard ratio: 1.495 (1.400-1.597) ^§	Mehra
COVID-19 (death)	Patient characteristics	Ethnicity [Asian vs. White]	Hazard ratio: 0.717 (0.668-0.769) ^§	Mehra
COVID-19 (death)	Comorbidities	Coronary artery disease [Present vs. Not present]	Hazard ratio: 1.134 (1.082-1.188) ^§	Mehra
COVID-19 (death)	Comorbidities	Congestive heart failure [Present vs. Not present]	Hazard ratio: 1.756 (1.609-1.915) ^§	Mehra
COVID-19 (death)	Comorbidities	Arrhythmia [Present vs. Not present]	Hazard ratio: 1.626 (1.504-1.758) ^§	Mehra
COVID-19 (death)	Comorbidities	Diabetes [Present vs. Not present]	Hazard ratio: 1.206 (1.151-1.264) ^§	Mehra
COVID-19 (death)	Comorbidities	Hypertension [Present vs. Not present]	Hazard ratio: 1.302 (1.252-1.355) ^§	Mehra
COVID-19 (death)	Comorbidities	Hyperlipidaemia [Present vs. Not present]	Hazard ratio: 1.125 (1.081-1.171) ^§	Mehra
COVID-19 (death)	Comorbidities	COPD [Present vs. Not present]	Hazard ratio: 1.190 (1.093-1.294) ^§	Mehra
COVID-19 (death)	Comorbidities	Smoking [Present vs. Not present]	Hazard ratio: 1.268 (1.201-1.340) ^§	Mehra
COVID-19 (death)	Comorbidities	Immunosuppressed [Present vs. Not present]	Hazard ratio: 1.081 (0.985-1.187) ^§	Mehra
COVID-19 (death)	Treatment	Concomitant medication [Treated with ACEi vs. Not received]	Hazard ratio: 0.566 (0.514-0.624) ^§	Mehra
COVID-19 (death)	Treatment	Concomitant medication [Treated with Statins vs. Not received]	Hazard ratio: 0.793 (0.736-0.855) ^§	Mehra
COVID-19 (death)	Treatment	Concomitant medication [Treated with ARBs vs. Not received]	Hazard ratio: 0.989 (0.914-1.071) ^§	Mehra
COVID-19 (death)	Complications	Sequential Organ Failure Assessment (SOFA) score [Abnormal vs. Normal]	Hazard ratio: 0.758 (0.726-0.792) ^§	Mehra
COVID-19 (death)	Laboratory Findings	Oxygen Saturation (SpO2) [Abnormal vs. Normal]	Hazard ratio: 1.664 (1.587-1.746) ^§	Mehra
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with chloroquine alone vs. Not received]	Hazard ratio: 1.365 (1.218-1.531) ^§	Mehra
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with hydroxychloroquine alone vs. Not received]	Hazard ratio: 1.335 (1.223-1.457) ^§	Mehra
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with chloroquine and macrolide vs. Not received]	Hazard ratio: 1.368 (1.273-1.469) ^§	Mehra
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with hydroxychloroquine and macrolide vs. Not received]	Hazard ratio: 1.447 (1.368-1.531) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 0.994 (0.991-0.997) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	BMI [1 unit increase vs. Not applicable]	Hazard ratio: 0.985 (0.976-0.994) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	Gender [Male vs. Female]	Hazard ratio: 0.966 (0.861-1.082) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	Ethnicity [Black vs. White]	Hazard ratio: 0.980 (0.822-1.168) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	Ethnicity [Hispanic vs. White]	Hazard ratio: 1.130 (0.910-1.402) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Patient characteristics	Ethnicity [Asian vs. White]	Hazard ratio: 0.943 (0.792-1.123) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Coronary artery disease [Present vs. Not present]	Hazard ratio: 1.830 (1.613-2.076) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Congestive heart failure [Present vs. Not present]	Hazard ratio: 3.914 (3.283-4.665) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Arrhythmia [Present vs. Not present]	Hazard ratio: 4.119 (3.525-4.812) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Diabetes [Present vs. Not present]	Hazard ratio: 0.848 (0.724-0.993) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Hypertension [Present vs. Not present]	Hazard ratio: 0.941 (0.831-1.065) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Hyperlipidaemia [Present vs. Not present]	Hazard ratio: 1.059 (0.938-1.195) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	COPD [Present vs. Not present]	Hazard ratio: 1.585 (1.256-2.001) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Smoking [Present vs. Not present]	Hazard ratio: 0.950 (0.796-1.133) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Comorbidities	Immunosuppressed [Present vs. Not present]	Hazard ratio: 0.815 (0.604-1.101) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Treatment	Concomitant medication [Treated with ACEi vs. Not received]	Hazard ratio: 1.044 (0.852-1.279) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Treatment	Concomitant medication [Treated with Statins vs. Not received]	Hazard ratio: 0.973 (0.797-1.187) ^§	Mehra
COVID-19 (ventricular arrhythmias)	Treatment	Concomitant medication [Treated with ARBs vs. Not received]	Hazard ratio: 1.043 (0.831-1.307) ^§	Mehra

If a relevant publication escaped our attention, please contact us.